March 5, 2018 / 1:11 PM / 9 months ago

BRIEF-Onconova Therapeutics Announces License Agreement With Pint Pharma To Commercialize Rigosertib

March 5 (Reuters) - Onconova Therapeutics Inc:

* ONCONOVA THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH PINT PHARMA TO COMMERCIALIZE RIGOSERTIB FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES IN LATIN AMERICA

* ONCONOVA THERAPEUTICS INC - ONCONOVA ALSO ELIGIBLE TO RECEIVE UP TO $42.75 MILLION IN REGULATORY AND SALES MILESTONES

* ONCONOVA THERAPEUTICS - IN EXCHANGE FOR RIGHTS, PINT WILL MAKE INVESTMENT TOTALING UP TO $2.5 MILLION BY PURCHASING SHARES AT A PREMIUM TO MARKET

* ONCONOVA THERAPEUTICS INC - RIGOSERTIB TOP-LINE DATA EXPECTED IN 2019 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below